Search

Your search keyword '"Vago,L"' showing total 6 results
Start Over Author "Vago,L" Journal leukemia
6 results on '"Vago,L"'

1. Incidence, risk factors and clinical outcome of leukemia relapses with loss of the mismatched HLA after partially incompatible hematopoietic stem cell transplantation

Author

Crucitti, L, Crocchiolo, R, Toffalori, C, Mazzi, B, Greco, R, Signori, A, Sizzano, F, Chiesa, L, Zino, E, Lupo Stanghellini, M T, Assanelli, A, Carrabba, M G, Marktel, S, Marcatti, M, Bordignon, C, Corti, C, Bernardi, M, Peccatori, J, Bonini, C, Fleischhauer, K, Ciceri, F, and Vago, L

Published
2015
Full Text
View/download PDF

2. Sirolimus-based graft-versus-host disease prophylaxis promotes the in vivo expansion of regulatory T cells and permits peripheral blood stem cell transplantation from haploidentical donors

Author

Peccatori, J, Forcina, A, Clerici, D, Crocchiolo, R, Vago, L, Stanghellini, M T L, Noviello, M, Messina, C, Crotta, A, Assanelli, A, Marktel, S, Olek, S, Mastaglio, S, Giglio, F, Crucitti, L, Lorusso, A, Guggiari, E, Lunghi, F, Carrabba, M, Tassara, M, Battaglia, M, Ferraro, A, Carbone, M R, Oliveira, G, Roncarolo, M G, Rossini, S, Bernardi, M, Corti, C, Marcatti, M, Patriarca, F, Zecca, M, Locatelli, F, Bordignon, C, Fleischhauer, K, Bondanza, A, Bonini, C, and Ciceri, F

Published
2015
Full Text
View/download PDF

4. Incidence, risk factors and clinical outcome of leukemia relapses with loss of the mismatched HLA after partially incompatible hematopoietic stem cell transplantation

Author

Crucitti, L, primary, Crocchiolo, R, additional, Toffalori, C, additional, Mazzi, B, additional, Greco, R, additional, Signori, A, additional, Sizzano, F, additional, Chiesa, L, additional, Zino, E, additional, Lupo Stanghellini, M T, additional, Assanelli, A, additional, Carrabba, M G, additional, Marktel, S, additional, Marcatti, M, additional, Bordignon, C, additional, Corti, C, additional, Bernardi, M, additional, Peccatori, J, additional, Bonini, C, additional, Fleischhauer, K, additional, Ciceri, F, additional, and Vago, L, additional

Published
2014
Full Text
View/download PDF

5. Sirolimus-based graft-versus-host disease prophylaxis promotes the in vivo expansion of regulatory T cells and permits peripheral blood stem cell transplantation from haploidentical donors

Author

Peccatori, J, primary, Forcina, A, additional, Clerici, D, additional, Crocchiolo, R, additional, Vago, L, additional, Stanghellini, M T L, additional, Noviello, M, additional, Messina, C, additional, Crotta, A, additional, Assanelli, A, additional, Marktel, S, additional, Olek, S, additional, Mastaglio, S, additional, Giglio, F, additional, Crucitti, L, additional, Lorusso, A, additional, Guggiari, E, additional, Lunghi, F, additional, Carrabba, M, additional, Tassara, M, additional, Battaglia, M, additional, Ferraro, A, additional, Carbone, M R, additional, Oliveira, G, additional, Roncarolo, M G, additional, Rossini, S, additional, Bernardi, M, additional, Corti, C, additional, Marcatti, M, additional, Patriarca, F, additional, Zecca, M, additional, Locatelli, F, additional, Bordignon, C, additional, Fleischhauer, K, additional, Bondanza, A, additional, Bonini, C, additional, and Ciceri, F, additional

Published
2014
Full Text
View/download PDF

6. Post-transplantation cyclophosphamide GvHD prophylaxis after hematopoietic stem cell transplantation from 9/10 or 10/10 HLA-matched unrelated donors for acute leukemia.

Author

Lorentino F, Labopin M, Ciceri F, Vago L, Fleischhauer K, Afanasyev B, Kröger N, Cornelissen JJ, Lovira M, Meijer E, Vitek A, Elmaagacli A, Blaise D, Ruggeri A, Chabannon C, Nagler A, and Mohty M

Subjects
Adolescent, Adult, Aged, Female, Follow-Up Studies, Graft vs Host Disease drug therapy, Graft vs Host Disease etiology, Graft vs Host Disease pathology, Histocompatibility Testing, Humans, Immunosuppressive Agents therapeutic use, Leukemia, Myeloid, Acute pathology, Leukemia, Myeloid, Acute therapy, Male, Middle Aged, Neoplasm Recurrence, Local pathology, Neoplasm Recurrence, Local therapy, Precursor Cell Lymphoblastic Leukemia-Lymphoma pathology, Precursor Cell Lymphoblastic Leukemia-Lymphoma therapy, Prognosis, Retrospective Studies, Survival Rate, Transplantation Conditioning, Transplantation, Homologous, Young Adult, Cyclophosphamide therapeutic use, Graft vs Host Disease mortality, Hematopoietic Stem Cell Transplantation adverse effects, Leukemia, Myeloid, Acute mortality, Neoplasm Recurrence, Local mortality, Precursor Cell Lymphoblastic Leukemia-Lymphoma mortality, Unrelated Donors
Abstract

HLA-matching largely contributes to unrelated donor hematopoietic cell transplantation (UD-HCT) success but, due to the selective deletion of alloreactive T-cells, post-transplantation cyclophosphamide (PTCy) could modulate its negative impact on outcomes. We retrospectively compared acute leukemia patients receiving 10/10 or 9/10 HLA allele-matched UD-HCT with PTCy-GvHD prophylaxis between 2010 and 2017, reported to EBMT registry. The 100-day incidence of grade ≥2 and grade ≥3 aGvHD were comparable for 10/10 and 9/10 UD (28% versus 28%, p = 0.8 and 10% versus 8%, p = 0.5, respectively). The 2-year cGvHD and extensive cGvHD were similar between 10/10 and 9/10 UD (35% versus 44%, p = 0.2 and 21% versus 20%, p = 0.6, respectively). The 2-year nonrelapse mortality was 20% after 10/10 and 16% after 9/10 UD-HCT (p = 0.1). Relapse incidence at 2-year was 24% for 10/10 and 28% for 9/10 UD-HCT (p = 0.4). Leukemia-free survival at 2-year was the same for 10/10 and 9/10 UD (56 and 56%, p = 0.6, respectively), with comparable overall survival (62 and 59%, p = 0.9, respectively). Multivariate analysis showed no effect of HLA-matching on outcomes. An advanced disease status and patient disability remained the most important factors portending a worse survival. PTCy could alleviate the detrimental effect of HLA-allele mismatching in UD-HCT, potentially expanding the donor pool for acute leukemia patients.

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results